ARCA biopharma Overview
Latest PEG ratio for ARCA biopharma: -80.24 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-80.24
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
ARCA biopharma's peg ratio stands at -80.24. That is below the Healthcare sector average of 1.26. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
ARCA biopharma sits lower the Healthcare benchmark (1.26) with a PEG ratio of -80.24. That is roughly 6482.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -80.24 is attractive depends on ARCA biopharma's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how ARCA biopharma's PEG ratio evolved across reporting periods, while the comparison chart places ABIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, PEG ratio is commonly used to spot outliers. ARCA biopharma's reading of -80.24 (sector avg 1.26) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
